Published in Genes Cancer on April 01, 2014
MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr (2015) 0.98
Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer. Int J Clin Exp Pathol (2015) 0.84
MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway. Oncotarget (2016) 0.83
MicroRNA‑20a promotes the proliferation and cell cycle of human osteosarcoma cells by suppressing early growth response 2 expression. Mol Med Rep (2015) 0.78
TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Mol Cancer (2017) 0.75
Prognostic value of microRNAs in osteosarcoma: A meta-analysis. Oncotarget (2017) 0.75
Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer. Oncol Lett (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol (2002) 10.03
The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ (2013) 2.41
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One (2012) 2.06
miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res (2011) 2.06
New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol (2013) 1.97
mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev (2013) 1.32
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol (1996) 1.26
Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res (2010) 1.25
Cancer genomes evolve by pulverizing single chromosomes. Cell (2011) 1.20
miR-92a family and their target genes in tumorigenesis and metastasis. Exp Cell Res (2014) 1.13
Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis. Curr Genomics (2010) 1.09
MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet (2012) 1.08
Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop Relat Res (1991) 1.05
miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog (2012) 1.01
Biomarkers in Osteosarcoma. Expert Opin Med Diagn (2009) 0.97
MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation. Endocrine (2013) 0.96
MicroRNA-17-92a upregulation by estrogen leads to Bim targeting and inhibition of osteoblast apoptosis. J Cell Sci (2012) 0.91
microRNA-17~92 is a powerful cancer driver and a therapeutic target. Cell Cycle (2014) 0.89
Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors. BMC Clin Pathol (2012) 0.80
Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry. Oral Oncol (2013) 0.79
HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia (2016) 0.76